

QIBA PET Amyloid Biomarker Committee (BC) Call

8 September 2017 at 9:00 AM CT

Call Summary

In attendance:			RSNA
<i>Dawn Matthews, MS, MBA (Co-Chair)</i>	Paul Kinahan, PhD	John Sunderand, PhD	Joe Koudelik
<i>Anne Smith, PhD (Co-Chair)</i>	Adriaan Lammertsma, PhD	Jean-Luc Vanderheyden, PhD	Julie Lisiecki
Christopher Buckley, PhD	Nancy Obuchowski, PhD	Richard Wahl, MD, FACR	
Anurag Gupta, PhD	Larry Pierce, PhD		

Moderator: Dr. Smith

PET Amyloid Poster for RSNA 2017:

- Dr. Perlman reviewed the poster guidelines from Drs. Jackson and Guimaraes:
 - Organizational Structure Updates
 - Profile Development Status
 - Profile Impact/Implications for Clinical Trials and Patient Care (new focus for 2017)
 - Conformance Procedure Update
 - Groundwork Project Status/Results (optional)
 - Additional content to include would be an interim update regarding the IDEAS study
- The [2016 poster](#) was reviewed to determine what updates were needed
- A Quick Guide PDF brochure (or QR code) for the Profile was discussed for additional information to accompany the poster
 - This could help clinicians understand how to use the Profile for best practices in a clinical setting, as well as for clinical trials
- Ms. Matthews volunteered to be the poster coordinator
- Dr. Gupta offered to draft some text regarding how the Profile can best be used in the clinic
- The due date for a print-ready PowerPoint version to RSNA staff is **October 31st**

DRO Update: (Drs. Pierce and Kinahan)

- A set of 30 DROs in DICOM format are ready for beta-testing
- Dr. Pierce to work on a protocol for testing
 - Guidance may be available in the Profile appendix
- Considerations for DRO testing include:
 - What regions should be evaluated
 - What reference regions should be used
 - What measures should be evaluated
 - What should be in the final report
 - Dr. Obuchowski to be consulted
 - Dr. Buckley volunteered his help also
 - Dr. Koeppe and Centiloid group may also be consulted
- Dr. Kinahan to reach out to Dr. Nelson at MIMVista
- Volunteers who have agreed to test the DRO include: GE, Siemens and MIMVista

Profile Public Comment Updates:

- The Profile was released for public comment on June 1st; six comments have been received to-date
- Public Comment ends on September 15th
- Committee members intend to follow up personally with colleagues in order to solicit targeted feedback
- Updates regarding the volunteer contacts for sister organizations are as follows:
 - Alzheimer's Association (Dr. Minoshima)
 - ADNI (Dr. Minoshima) –[contacted](#)
 - GAAIN (Dr. Minoshima)
 - FNIIH (Drs. Wahl and Benzinger)
 - AFAR (Dr. Vanderheyden) –[contacted](#)
 - NIA (Drs. Wahl and Minoshima to contact Peter H. and others)
 - European and Japanese Initiatives (Dr. Boellaard)
 - Human Amyloid Imaging Group (Dr. Subramaniam and Ms. Matthews)
 - SNMMI Brain Council (already have Profile) –[contacted](#)
 - Keith Johnson, MGH, and Coordinator for Human Amyloid Imaging Meeting (Dr. Gupta) –[contacted](#)
 - AMYPAD European Consortium, will collect 6k scans/ 4 years (Dr. Lammerstma) –[contacted](#)
 - International Committee for MR and PET imagers (Dr. Benzinger)
 - Centiloid Working Group (Dr. Benzinger) –[contacted](#)
 - NIH Alzheimer's Disease Centers Imaging Steering Committee (Dr. Benzinger) –[contacted](#)
 - Dominantly Inherited Alzheimer Network (DIAN) Imaging Committee –[contacted](#)
 - European Association of Nuclear Medicine (Neuro) –[contacted](#)
 - Julie Price ([Ms. Matthews to contact after Sept 20th](#))
 - Dr. Buckley ([aiding with the claim development](#))
 - Dr. Benzinger ([received feedback](#))
 - GE Healthcare ([received feedback](#))
- Boilerplate text regarding the value of the Amyloid Profile is needed when reaching out to sister organizations, to include:
 - Brief background with purpose and intended audience/use of the profile
 - What types of comments are requested, and suggested method for providing (e.g. the Excel spreadsheet)
- A strategy to triage and address comments is under development; co-chairs will review comment resolution spreadsheets from FDG-PET, SPECT, and MR Profiles and incorporate feedback

Open Issues requiring resolution include:

- Claim context and tolerance
- Conformance methodology (draft plan)
 - Region segmentation requirements
- Conformance testing (draft plan)
- Reference section

Action items:

- All: volunteer liaisons to solicit feedback for the Profile be submitted by the September 15th deadline
- Dr. Smith and Ms. Matthews to work on approach to resolve profile claim
- Drs. Kinahan, Pierce and team to complete DRO evaluation protocol for testing and feedback
- Ms. Matthews to draft poster and circulated prior to next BC call (10/13) for feedback

NM WebEx Schedule

9/15	SPECT BC
9/29	NM Coordinating Ctte
10/6	FDG-PET BC
10/13	PET-Amyloid BC
10/20	SPECT BC
10/31	PPT print-ready posters due to RSNA

SPECT Task Forces

10/3	I-123 Profile Comment Resolution
10/10	TC 99m Profile Development

SAVE-THE-DATE:



QIBA Working Meeting at RSNA 2017 | Wednesday,
November 29, 2:30-6 pm – Lakeside Center, McCormick
Place